FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * MPM BioVentures IV QP LP   2. Issuer Name and Ticker or Trading Symbol CHIASMA, INC [CHMA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O MPM CAPITAL, 450 KENDALL STREET 3. Date of Earliest Transaction (Month/Day/Year) 07/21/2015 (Street) CAMBRIDGE, MA 02142 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) ___ Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 07/21/2015   C   10,426 (1) A (2) 10,426 I See Footnote (3) Common Stock 07/21/2015   C   2,488,171 (4) A (2) 2,498,597 I See Footnote (5) Common Stock 07/21/2015   C   1,759,381 (6) A (2) 4,257,978 I See Footnote (7) Common Stock 07/21/2015   C   1,423,566 (8) A (2) 5,681,544 I See Footnote (9)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Series B-1' Preferred Stock

(2)

07/21/2015

C

95,225 (1)

(2)

(2)

Common Stock

10,426 (1)

(2)

0

I

See Footnote (1)

Series C' Preferred Stock

(2)

07/21/2015

C

22,721,988 (4)

(2)

(2)

Common Stock

2,488,171 (4)

(2)

0

I

See Footnote (4)

Series D' Preferred Stock

(2)

07/21/2015

C

16,066,669 (6)

(2)

(2)

Common Stock

1,759,381 (6)

(2)

0

I

See Footnote (6)

Series E Preferred Stock

(2)

07/21/2015

C

13,000,000 (8)

(2)

(2)

Common Stock

1,423,566 (8)

(2)

0

I

See Footnote (8)

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
MPM BioVentures IV QP LP C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA 02142		X
EVNIN LUKE C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA 02142		X
Scopa James Paul C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA 02142		X
KAILIAN VAUGHN M C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA 02142		X
MPM Asset Management Investors BV4 LLC C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA 02142		X
MPM Bio IV NVS Strategic Fund LP C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA 02142		X
MPM BioVentures IV GmbH & Co. Beteiligungs KG C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA 02142		X
MPM BioVentures IV GP LLC C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA 02142		X
MPM BioVentures IV LLC C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA 02142		X

Signatures

By Luke Evnin, member of MPM BioVenture IV LLC, the managing member of MPM BioVentures IV GP LLC, the general partner of MPM BioVentures IV-QP, L.P. /s/ Luke Evnin		07/21/2015
**Signature of Reporting Person		Date
/s/ Luke Evnin		07/21/2015
**Signature of Reporting Person		Date
/s/ James Paul Scopa		07/21/2015
**Signature of Reporting Person		Date
/s/ Vaughn M. Kailian		07/21/2015
**Signature of Reporting Person		Date
By Luke Evnin, member of MPM BioVenture IV LLC, the manager of MPM Asset Management Investors BV4 LLC /s/ Luke Evnin		07/21/2015
**Signature of Reporting Person		Date
By Luke Evnin, member of MPM BioVenture IV LLC, the managing member of MPM BioVentures IV GP LLC, the general partner of MPM Bio IV NVS Strategic Fund, L.P. /s/ Luke Evnin		07/21/2015
**Signature of Reporting Person		Date
By Luke Evnin, member of MPM BioVenture IV LLC, the managing member of MPM BioVentures IV GP LLC, the managing limited partner of MPM BioVentures IV GmbH & Co. Beteiligungs KG /s/ Luke Evnin		07/21/2015
**Signature of Reporting Person		Date
By Luke Evnin, member of MPM BioVentures IV LLC, the managing member of MPM BioVentures IV GP LLC /s/ Luke Evnin		07/21/2015
**Signature of Reporting Person		Date
By Luke Evnin, member of MPM BioVenture IV LLC /s/ Luke Evnin		07/21/2015
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The shares, on a common stock equivalent basis, were converted as follows: 9,773 by MPM BioVentures IV-QP, L.P. ("BV IV QP"), 376 by MPM BioVentures IV GmbH & Co. Beteiligungs KG ("BV IV KG") and 277 by MPM Asset Management Investors BV4 LLC ("AM BV4"). MPM BioVentures IV GP LLC ("BV GP LLC") and MPM BioVentures IV LLC ("BV LLC") are the direct and indirect general partners of BV IV QP and BV IV KG and BV LLC is the manager of AM BV4. Ansbert Gadicke, Luke Evnin, Vaughn M. Kailian, James Paul Scopa and Todd Foley are the members of BV LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
(2)	The shares of Series B-1' Preferred Stock, Series C' Preferred Stock, Series D' Preferred Stock and Series E Preferred Stock converted into 0.109505 of a share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date.
(3)	The shares are held as follows: 9,773 by BV IV QP, 376 by BV IV KG and 277 by AM BV4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
(4)	The shares, on a common stock equivalent basis, were converted as follows: 1,479,910 by BV IV QP, 57,016 by BV IV KG, 42,083 by AM BV4 and 909,162 by MPM Bio IV NVS Strategic Fund, L.P. ("BV IV SF"). BV GP LLC and BV LLC are the direct and indirect general partners of BV IV SF. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
(5)	The shares are held as follows: 1,489,683 by BV IV QP, 57,392 by BV IV KG, 42,360 by AM BV4 and 909,162 by BV IV SF. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
(6)	The shares, on a common stock equivalent basis, were converted as follows: 1,539,486 by BV IV QP, 59,313 by BV IV KG, 43,776 by AM BV4 and 116,806 by BV IV SF. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
(7)	The shares are held as follows: 3,029,169 by BV IV QP, 116,705 by BV IV KG, 86,136 by AM BV4 and 1,025,968 by BV IV SF. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
(8)	The shares, on a common stock equivalent basis, were converted as follows: 939,089 by BV IV QP, 36,179 by BV IV KG, 26,704 by AM BV4 and 421,594 by BV IV SF. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
(9)	The shares are held as follows: 3,968,258 by BV IV QP, 152,884 by BV IV KG, 112,840 by AM BV4 and 1,447,562 by BV IV SF. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.